Abstract
Polyomavirus and human papillomavirus (HPV) virus-like particles (VLPs) can be obtained by producing their major capsid protein VP1 (for polyomavirus) or L1 (for HPV) free from other viral genes in, for example, a baculovirus insect system, yeast, Escherichia coli or similar systems. Polyomavirus and HPV VLPs can immunize healthy individuals, and in some cases T-cell-deficient hosts, against primary infection with the corresponding virus. Chimeric VLPs from polyomaviruses or HPVs containing fusion proteins between the VP1/L1 or VP2/VP3/L2 minor capsid proteins and selected antigens can also be produced. These VLPs can then induce B- or T-cell immune responses and be used as preventive or therapeutic vaccines against cancers induced by the corresponding virus, or a cancer bearing the selected tumor antigen.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Alphapapillomavirus / genetics
-
Alphapapillomavirus / immunology*
-
Animals
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / metabolism
-
B-Lymphocytes / drug effects
-
B-Lymphocytes / pathology
-
Capsid Proteins / genetics
-
Capsid Proteins / metabolism
-
Humans
-
Immunization
-
Immunotherapy*
-
Lymphocyte Activation
-
Neoplasms / drug therapy*
-
Neoplasms / immunology
-
Neoplasms / pathology
-
Neoplasms / virology
-
Oncogene Proteins, Viral / genetics
-
Oncogene Proteins, Viral / metabolism
-
Polyomavirus / genetics
-
Polyomavirus / immunology*
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / metabolism
-
Recombinant Fusion Proteins / therapeutic use
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / pathology
-
Virion / genetics
-
Virion / metabolism*
Substances
-
Antigens, Neoplasm
-
Capsid Proteins
-
HPV L1 protein, Human papillomavirus
-
Oncogene Proteins, Viral
-
Recombinant Fusion Proteins
-
VP1 protein, polyomavirus